相关实验视频
Updated: Jul 2, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
858
在急性冠状动脉综合征患者中,平均血小板体积和血小板聚合研究之间的相关性研究
1Department of Pathology, Chettinad Academy of Research and Education, Kelambakkam, Chengalpattu, Tamil Nadu, India.
Indian journal of pathology & microbiology
|February 23, 2024
概括
在急性冠状动脉综合征 (ACS) 患者中血小板平均体积 (MPV) 升高并不意味着血小板过度反应. 这一发现表明,增加的MPV可能反映出由于血栓形成中的消耗而导致更大的不成熟血小板释放.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 血栓形成的原因之一是血栓形成.
背景情况:
- 血小板在心血管疾病的发病过程中至关重要,特别是在急性血栓事件中.
- 血小板指数升高被研究为急性冠状动脉综合征 (ACS) 的潜在危险因素.
- 血小板指数增加和ACS之间的因果关系尚不清楚.
研究的目的:
- 研究ACS患者中平均血小板体积 (MPV) 和血小板聚合反应之间的相关性.
- 评估血小板的功能状态与其大小相关.
主要方法:
- 纳入了50名患有ST段升高ACS (STE-ACS) 或非ST段升高ACS (NSTE-ACS) 的患者.
- 测量了平均血小板体积 (MPV),并进行了血小板聚合计.
- 患者根据MPV (≤9.1 fL与>9.1 fL) 进行分组,并将平均最大血小板聚合反应 (MMPAR) 与ADP,原蛋白和上腺素进行比较.
主要成果:
- 在低MPV和高MPV组之间没有观察到MMPAR与ADP,原或上腺素的统计学上显著差异.
- 在低MPV组中,MMPAR与ADP的比例为74.47%,在高MPV组中为72.94%.
- 在低MPV组中,原的MMPAR为66.13%,在高MPV组中为59.97%.
- 在低MPV组中,MMPAR与上腺素的比例为72.9%,在高MPV组中为72.43%.
结论:
- 在ACS患者中,增加的平均血小板体积 (MPV) 不等于高反应性血小板.
- 升高的MPV可能表明骨髓中不成熟的血小板的释放增加.
- 这种现象可能是由于ACS中的血栓形成部位的血小板消耗增加的次要原因.
相关概念视频
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523